ICD-10 codes for kidney cancer

In the vast, intricate language of modern healthcare, where patient stories are translated into data, few systems are as fundamental as the International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM). To the uninitiated, a code like C64.1 may seem like an arcane string of characters, a bureaucratic necessity devoid of human context. But for the medical coder, the clinician, the researcher, and, most importantly, the patient, this code tells a profound story. It is the story of a diagnosis, a journey, and a battle fought within the silent, bean-shaped organs that filter our blood—the kidneys.

Kidney cancer, while not the most common malignancy, represents a significant health burden with over 400,000 new cases diagnosed worldwide each year. Its diagnosis sets in motion a complex cascade of events: treatment planning, prognostic discussions, surgical interventions, systemic therapies, and long-term surveillance. At the heart of this clinical whirlwind lies the humble ICD-10 code. This code is the key that unlocks insurance reimbursement, ensures accurate documentation in the electronic health record (EHR), populates cancer registries that track disease trends, and facilitates the critical research that leads to new discoveries.

This article is designed to be the definitive guide to ICD-10 codes for kidney cancer. We will move beyond simple code lists and delve into the clinical rationale, anatomical precision, and procedural nuances that define expert-level coding. From the basic structure of the neoplasm chapter to the complexities of coding for metastatic disease and genetic subtypes, we will equip you with the knowledge to assign these codes with confidence and accuracy. Whether you are a seasoned medical coder, a healthcare administration student, a clinical professional, or simply someone seeking to understand this critical aspect of healthcare documentation, the following chapters will provide a comprehensive, detailed, and exclusive exploration of the subject.

Chapter 1: Understanding the Landscape – An Overview of Kidney Cancer

Before one can accurately code a disease, one must understand it. Kidney cancer is not a single entity but a group of cancers that originate in the kidney. A firm grasp of renal anatomy and pathology is the bedrock upon which accurate ICD-10 coding is built.

The Vital Role of the Kidneys

The kidneys are two retroperitoneal organs located on either side of the spine, just below the rib cage. Their primary functions are crucial for sustaining life:

• Filtration and Waste Removal: They filter blood to remove toxins, metabolic waste, and excess ions, forming urine.

• Homeostasis: They regulate blood volume, pressure, pH, and electrolyte concentrations (e.g., sodium, potassium, calcium).

• Endocrine Functions: They produce hormones like erythropoietin (which stimulates red blood cell production) and renin (which regulates blood pressure).

The functional unit of the kidney is the nephron, which consists of a glomerulus and a tubule. Most kidney cancers arise from the lining of the tubules.

What is Kidney Cancer?

Kidney cancer, or renal cancer, occurs when cells in the kidney grow uncontrollably, forming a mass called a tumor. A critical distinction is made between:

• Benign Tumors: Non-cancerous growths that do not spread to other parts of the body (e.g., renal oncocytoma). While they may grow and cause problems locally, they are not coded as malignancies.

• Malignant Tumors: Cancerous growths that can invade surrounding tissues and metastasize (spread) to distant organs, such as the lungs, bones, liver, or brain.

Major Types of Kidney Cancer: A Clinical Primer

The histologic type—what the cancer cells look like under a microscope—is the single most important factor in classifying kidney cancer, as it influences prognosis and treatment. ICD-10 coding requires this specificity.

• Renal Cell Carcinoma (RCC): This is the most common type, accounting for approximately 90% of all kidney cancers in adults. RCC itself has several major subtypes:

  • Clear Cell RCC (ccRCC): The most prevalent subtype (70-80%), named for the pale, clear appearance of the cells.

  • Papillary RCC (pRCC): The second most common subtype (10-15%), characterized by finger-like projections in the tumor.

  • Chromophobe RCC (chRCC): A less common subtype (5%) with a generally better prognosis than clear cell and papillary RCC.

  • Collecting Duct Carcinoma and Renal Medullary Carcinoma: Very rare and aggressive subtypes.

• Urothelial Carcinoma (Transitional Cell Carcinoma – TCC): This cancer does not originate in the kidney parenchyma itself but in the renal pelvis—the funnel-like area where the kidney collects urine before it drains into the ureter. Histologically, it is identical to bladder cancer and is coded differently from RCC. It accounts for about 5-10% of all kidney cancers.

• Wilms’ Tumor (Nephroblastoma): This is the most common type of kidney cancer in children, typically diagnosed before the age of 5. It is distinct from adult RCC in its pathology, genetics, and treatment.

• Rare Kidney Cancers: These include renal sarcomas (cancer of the kidney’s connective tissue) and other even rarer entities.

Chapter 2: The Foundation of Medical Coding – Demystifying the ICD-10-CM System

To navigate the specific codes for kidney cancer, one must first understand the system that contains them.

What is ICD-10-CM?

The International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) is the official system for assigning codes to diagnoses and procedures in the United States. It is maintained by the Centers for Disease Control and Prevention (CDC) and the National Center for Health Statistics (NCHS). Its primary purposes are:

• Standardization: Creating a universal language for diseases and health conditions.

• Reimbursement: Serving as the foundation for billing and insurance claims, particularly with diagnosis-related groups (DRGs).

• Epidemiology and Research: Tracking morbidity and mortality rates, identifying disease outbreaks, and facilitating public health research.

• Quality Measurement: Helping to measure the quality, safety, and efficacy of patient care.

The Structure of an ICD-10-CM Code

An ICD-10-CM code is alphanumeric and consists of 3 to 7 characters. The structure is hierarchical:

• Chapter: The first character is a letter, representing the broad chapter (e.g., ‘C’ for certain infectious and parasitic diseases, but more relevantly, ‘C’ for Neoplasms).

• Category: The first three characters (e.g., C64) define the general category of the disease.

• Etiology, Anatomic Site, Severity, and Other Detail: Characters 4 through 7 provide increasing levels of specificity. The 4th and 5th characters often specify the anatomic site, the 6th character may specify laterality (left, right, bilateral), and the 7th character can be an extension for use in certain circumstances (like encounter type for injuries and external causes).

The Importance of Accurate Kidney Cancer Coding

Incorrect coding is not merely a clerical error; it has real-world consequences:

• Claim Denials and Financial Loss: Using an unspecified code when a specific code is available, or misrepresenting laterality, can lead to claim rejections or denials.

• Compromised Patient Care: Inaccurate data in the EHR can lead to miscommunication among providers and potentially affect treatment decisions.

• Flawed Public Health Data: If codes are not assigned correctly, the national data on kidney cancer incidence, prevalence, and outcomes become unreliable, hindering research and resource allocation.

• Legal and Compliance Risks: Knowingly incorrect coding for financial gain is fraud, with severe penalties.

Chapter 3: A Deep Dive into the Codes – The ICD-10-CM Chapter for Neoplasms (C00-D49)

Chapter 2 of the ICD-10-CM manual is dedicated to neoplasms. It is organized by anatomical site and behavior (malignant, in situ, benign, etc.). For kidney cancer, we are primarily concerned with the C64 and C65 categories.

The Structure of Chapter 2: Neoplasms

The neoplasm table in the ICD-10 manual is organized by anatomical site. For each site, you will find codes for:

• Malignant, Primary

• Malignant, Secondary (Metastatic)

• In Situ

• Benign

• Uncertain Behavior

• Unspecified Behavior

The C64 Series: Malignant Neoplasm of Kidney, Except Renal Pelvis

This category is used for the vast majority of kidney cancers, specifically Renal Cell Carcinomas (RCC) and other primary malignancies of the kidney parenchyma.

• C64.0 – Malignant neoplasm of right kidney, except renal pelvis

• C64.1 – Malignant neoplasm of left kidney, except renal pelvis

• C64.2 – Malignant neoplasm of unspecified kidney, except renal pelvis

Coding Note: The codes C64.0 and C64.1 require a 6th character to specify the type of encounter or the morphology, but in the case of neoplasms, the 6th character is typically used to specify laterality, which is already built into the code. For neoplasms, the Tabular List instructs coders to “Use additional code to identify any functional activity.” This is rarely used for kidney cancer but could be relevant if, for example, the tumor is producing ectopic hormones.

The C65 Series: Malignant Neoplasm of Renal Pelvis

This category is used exclusively for urothelial carcinomas (transitional cell carcinomas) that arise in the renal pelvis. It is critical not to confuse this with cancers of the kidney parenchyma.

• C65.0 – Malignant neoplasm of right renal pelvis

• C65.1 – Malignant neoplasm of left renal pelvis

• C65.2 – Malignant neoplasm of unspecified renal pelvis

Coding Note: The distinction between C64 and C65 is one of the most common areas for error. The coder must rely on the pathology report. If the report states “renal cell carcinoma,” the code is from C64. If it states “urothelial carcinoma” or “transitional cell carcinoma” of the kidney, the code is from C65.

The C79.0 Code: Secondary Malignant Neoplasm of Kidney

This code is used when cancer has spread to the kidney from a primary site elsewhere in the body. For example, lung cancer or melanoma can metastasize to the kidney.

• C79.00 – Secondary malignant neoplasm of unspecified kidney

• C79.01 – Secondary malignant neoplasm of right kidney

• C79.02 – Secondary malignant neoplasm of left kidney

Coding Note: When coding a secondary neoplasm, you must first code the primary malignancy (e.g., C34.90 for lung cancer) and then code the secondary site (C79.01).

The D41.1 and D41.2 Codes: Neoplasms of Uncertain Behavior of the Kidney and Renal Pelvis

These codes are used when a mass is found, and a biopsy is performed, but the pathologist cannot definitively determine if it is benign or malignant.

• D41.10 – Neoplasm of uncertain behavior of unspecified kidney

• D41.11 – Neoplasm of uncertain behavior of right kidney

• D41.12 – Neoplasm of uncertain behavior of left kidney

• D41.20 – Neoplasm of uncertain behavior of unspecified renal pelvis

• D41.21 – Neoplasm of uncertain behavior of right renal pelvis

• D41.22 – Neoplasm of uncertain behavior of left renal pelvis

The D49.5 Code: Neoplasms of Unspecified Behavior of Other Genitourinary Organs

This code is a last resort and should be used sparingly. It is only appropriate when there is a documented mass or neoplasm, but no clinical, radiographic, or pathological information is available to determine its behavior (benign, malignant, or uncertain). Its use is heavily scrutinized by payers.

Chapter 4: Beyond the Primary Code – The Critical Role of Laterality and Morphology

Specificity is the golden rule in ICD-10 coding. For kidney cancer, this means specifying not just what and where, but also on which side.

The Sixth Character: Specifying Laterality

As seen in the C64 and C65 categories, laterality (left, right, bilateral) is a fundamental component of the code. The ICD-10-CM guidelines provide specific instructions for bilateral sites. If a patient has bilateral tumors, and there is no single code for “bilateral,” you should assign separate codes for both the left and right side.

The Importance of Morphology (Histology) Codes

While the primary ICD-10-CM code (like C64.1) identifies the location and behavior of the neoplasm, it does not always specify the histologic type. This is where morphology codes from the International Classification of Diseases for Oncology, Third Edition (ICD-O-3) come into play. These codes are primarily used by cancer registrars but are increasingly important in EHRs for precision medicine.

A morphology code has two parts: a five-digit code where the first four digits specify the histology and the fifth digit after the slash (/) specifies the behavior. For example:

• 8140/3 – Adenocarcinoma, NOS (this is a general code, often used for RCC)

• 8310/3 – Clear cell adenocarcinoma, NOS (commonly used for clear cell RCC)

• 8260/3 – Papillary adenocarcinoma, NOS (used for papillary RCC)

• 8120/3 – Transitional cell carcinoma, NOS (used for urothelial carcinoma of the renal pelvis, C65.x)

 Common Kidney Cancer Histologies and Corresponding ICD-10-CM and Morphology Codes

Chapter 5: The Coding Process in Action – A Step-by-Step Guide with Clinical Scenarios

The best way to understand coding is to see it applied. Let’s walk through several common clinical scenarios.

Scenario 1: Initial Diagnosis of Clear Cell RCC, Right Kidney

• Clinical Documentation: A 65-year-old male presents with hematuria. A CT scan reveals a 5cm mass in the mid-pole of the right kidney. A CT-guided biopsy is performed.

• Pathology Report: “Malignant neoplasm, consistent with clear cell renal cell carcinoma.”

• Coding Steps:

  1. Identify the site: Kidney, but not the renal pelvis.

  2. Identify the behavior: Malignant (primary).

  3. Identify the laterality: Right.

  4. Assigned Code: C64.0 – Malignant neoplasm of right kidney, except renal pelvis.

• Additional Consideration: For cancer registry purposes, the morphology code 8310/3 would also be assigned.

Scenario 2: Metastatic Urothelial Carcinoma of the Left Renal Pelvis

• Clinical Documentation: A patient with a known history of urothelial carcinoma of the left renal pelvis, status-nephrectomy, now presents with new lung nodules. Biopsy of a lung nodule confirms metastatic urothelial carcinoma.

• Coding Steps:

  1. The primary cancer is the urothelial carcinoma of the renal pelvis.

  2. Identify the site: Renal Pelvis.

  3. Identify the behavior: Malignant (primary).

  4. Identify the laterality: Left.

  5. The secondary (metastatic) site is the lung.

  6. Assigned Codes: C65.1 – Malignant neoplasm of left renal pelvis (primary) first, followed by C78.01 – Secondary malignant neoplasm of right lung (or C78.02 for left, depending on documentation).

Scenario 3: Follow-up Visit for a Patient with a History of Resected Wilms’ Tumor

• Clinical Documentation: A 10-year-old patient is seen for a routine annual follow-up. She had a left nephrectomy for Wilms’ tumor at age 3 and has been in remission since.

• Coding Steps:

  1. The patient no longer has active cancer. She has a personal history of cancer.

  2. Assigned Code: Z85.22 – Personal history of malignant neoplasm of kidney. This is the correct code for all follow-up and surveillance encounters once active treatment is complete and there is no evidence of disease.

Scenario 4: Incidental Finding of a Small Renal Mass, Unspecified

• Clinical Documentation: A patient has a CT scan for abdominal pain. The report states: “Incidental 1.5 cm enhancing lesion in the upper pole of the right kidney. No other abnormalities. Recommend urology consultation.” The patient has not had a biopsy.

• Coding Steps:

  1. There is a documented mass, but its behavior (benign vs. malignant) is unknown.

  2. It has not been biopsied, so it is not “uncertain behavior” (D41.11).

  3. The reason for the encounter is the abnormal finding.

  4. Assigned Code: R93.49 – Abnormal findings on diagnostic imaging of other body structures (as the kidney is not listed in the other R93.x codes). You would NOT use a neoplasm code because the behavior is completely unknown.

Chapter 6: Navigating Complexities and Pitfalls in Kidney Cancer Coding

Personal History of Malignant Neoplasm of Kidney (Z85.22)

This is one of the most frequently misused codes. It is only for patients who have completed treatment and are under surveillance, with no current evidence of the disease. If a patient is undergoing active chemotherapy, radiation, or is being monitored for possible recurrence with stable disease, the primary malignancy code (C64.x or C65.x) is still appropriate.

Coding for Patients Undergoing Active Treatment

Even if the primary kidney tumor has been surgically removed, if the patient is receiving adjuvant therapy (e.g., chemotherapy for metastatic RCC), the primary malignancy code remains the principal diagnosis. The cancer is still considered “active” from a coding perspective.

Distinguishing Between Primary, Secondary, and Uncertain Neoplasms

Always defer to the physician’s documentation and the pathology report. If there is any ambiguity, query the provider. Never assume the behavior or primary site of a neoplasm.

The Impact of Inaccurate Coding: Denials, Audits, and Data Integrity

As previously mentioned, errors lead to financial loss for healthcare providers and corrupt the national data used to fight cancer. Regular internal audits and continuous coder education are essential to maintain accuracy.

Chapter 7: The Intersection of Coding, Clinical Care, and Research

The role of the ICD-10 code extends far beyond the billing office.

How Accurate Coding Drives Quality Patient Care

Precise codes ensure that a patient’s electronic health record accurately reflects their complete medical history. This allows any provider accessing the record to quickly understand the patient’s cancer type, location, and history, leading to better-coordinated care.

The Role of ICD-10 Codes in Cancer Registries and Epidemiological Research

Hospital and national cancer registries rely on ICD-10 and ICD-O-3 codes to collect data on every cancer patient. This data is used to:

• Calculate cancer incidence and survival rates.

• Identify geographic or demographic clusters of specific cancer types.

• Monitor the effectiveness of public health initiatives and screening programs.

• Facilitate clinical trial recruitment by identifying eligible patient populations.

The Future: ICD-11 and Precision Medicine

The World Health Organization has already released ICD-11. While the US has not yet set a transition date, ICD-11 offers even greater granularity and is designed for a digital world. It allows for more precise coding of genetic subtypes and molecular markers, which are becoming increasingly critical in oncology. For example, future coding for kidney cancer may involve specific codes for tumors with specific genetic mutations like VHL, MET, or FH.

Conclusion

The assignment of an ICD-10 code for kidney cancer is a critical process that blends clinical knowledge with administrative precision. It requires a deep understanding of renal anatomy, cancer pathology, and the hierarchical structure of the coding system itself. From the common C64.1 for left-sided RCC to the specific C65.0 for right renal pelvis urothelial carcinoma, each code tells a precise story that impacts patient care, healthcare economics, and the global fight against cancer. By moving beyond memorization to comprehension, medical coders become invaluable partners in the healthcare ecosystem, ensuring that the data generated is as accurate and meaningful as the clinical care it supports.

Frequently Asked Questions (FAQs)

1. What is the difference between ICD-10 code C64.9 and C64.1?

• C64.1 is “Malignant neoplasm of left kidney, except renal pelvis.” It is specific to the left kidney.

• C64.9 is “Malignant neoplasm of unspecified kidney, except renal pelvis.” It is used when the medical record does not specify whether the tumor was in the right or left kidney. You should always use a specified code (C64.0 or C64.1) if the information is available.

2. When do I use a code from the C65 category instead of C64?

• Use C64 for cancers arising from the kidney’s functional tissue (parenchyma), like Renal Cell Carcinoma (RCC).

• Use C65 for cancers arising from the renal pelvis, which is the drainage system of the kidney. These are almost always Urothelial Carcinomas (also called Transitional Cell Carcinomas). The pathology report is definitive.

3. What code do I use for a benign kidney tumor, like an oncocytoma?

• Benign kidney tumors are not coded in the C64 category. A common benign tumor, renal oncocytoma, is coded to D17.11 (Benign lipomatous neoplasm of right kidney) or D17.12 (Benign lipomatous neoplasm of left kidney). Other benign tumors would be found in the D10-D36 chapter of ICD-10-CM.

4. How do I code a patient who had kidney cancer but is now in remission?

• Once active treatment is complete and there is no evidence of disease, the correct code is Z85.22 – Personal history of malignant neoplasm of kidney. This is used for all surveillance and follow-up encounters.

5. What is a morphology code, and do I have to use it with ICD-10?

• A morphology code (from ICD-O-3) describes the histologic type of the tumor (e.g., clear cell, papillary). For standard medical billing (outpatient/inpatient claims), it is not required. However, it is mandatory for cancer registrars who report data to state and national cancer registries. Its use in general EHRs is growing.

Additional Resources

1. CDC’s ICD-10-CM Official Guidelines for Coding and Reporting: https://www.cdc.gov/nchs/icd/icd-10-cm.htm (The definitive source for coding rules).

2. American Cancer Society – Kidney Cancer: https://www.cancer.org/cancer/kidney-cancer.html (Excellent for clinical background).

3. National Cancer Institute (NCI) – Renal Cell Cancer Treatment: https://www.cancer.gov/types/kidney/patient/kidney-treatment-pdq (In-depth clinical information).

4. American Health Information Management Association (AHIMA): https://www.ahima.org/ (Professional association for medical coders, offering education and resources).

5. World Health Organization (WHO) Classification of Tumours (Blue Books): The standard reference for pathology definitions and classifications of all tumors, including kidney cancers.

Date: October 10, 2025
Author: The Medical Coding Specialist Team
Disclaimer: The information contained in this article is for educational and informational purposes only and is not intended as a substitute for professional medical coding advice, diagnosis, or treatment. Always consult official ICD-10-CM coding guidelines, payer-specific policies, and a qualified medical coding professional for specific guidance. The authors and publishers are not responsible for any errors or omissions or for the results obtained from the use of this information.